Welcome back to the channel.

This is Plenary Session, a podcast at the intersection of medicine, oncology, and health policy.

You're watching the video feed and some of you are listening to the audio feed.

If you're on the audio feed, this time I've got slides, you're going to want to hop over.

And what we're talking about today is the enact trial.

A lot of people have asked for my opinion about the enact trial.

I think they know what they're going to get.

And this is, of course, a new study out now in JAM Oncology, active surveillance plus

enzaludamide monotherapy versus active surveillance alone in patients with low risk or intermediate

risk, localized prostate cancer, the enact study, a phase two study of enzymide. That's right, the extremely costly, something in the ballpark of $130,000 to $180,000 of year medication, enzaludamide, the androgen receptor antagonist in localized prostate cancer, where your control arm is a healthy dose of active surveillance, because that's what you'd otherwise do in this

setting and this is quite the study quite the study the first thing i always say when i read these

studies is this and i'm then i keep saying it somebody said you know you've laid off it recently i was

like well let me get right back on it uh We want to thank the patients and investigators who participated.

That's sweet.

That's nice.

I can get behind that.

And then medical writing assistance was provided by blah, blah, blah, blah.

And editorial support was provided by blah, blah, blah, blah, from blah, blah, blah, which

is funded by the study sponsors.

Medical writers.

Medical writers.

Do you, what would you say if kids in middle school and high school got medical writers to do their homework for them?

...